文献速递血栓与止血

BAY 94-9027(一种半衰期延长的凝血因子VIII)的安全性与有效性

Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
PubMed 文献 · J Thromb Haemost · 2017-02-22

这项跨国2/3期部分随机开放标签试验评估了聚乙二醇化长效重组凝血因子VIII BAY 94-9027 在重型A型血友病患者中的预防和治疗效果。132例患者接受预防或按需治疗,结果显示不同个体化给药方案均能预防出血,90.6%的出血经≤2次输注得到控制,无患者产生因子VIII抑制物。

要点

  • BAY 94-9027可预防出血,给药间隔最长可达每7天一次
  • 90.6%(636/702)的出血经≤2次输注得到控制
  • 无患者产生因子VIII抑制物

核心结论

  • BAY 94-9027通过三种个体化给药方案预防出血,且对出血治疗有效。
  • 无患者产生因子VIII抑制物。

研究设计与样本

  • 跨国、2/3期、部分随机、开放标签试验,纳入12-65岁、FVIII<1%且既往FVIII暴露≥150天的男性重型A型血友病患者。
  • 患者在10周导入期接受25 IU/kg每周两次给药后,进入36周按需或预防治疗;导入期出血>1次者接受30-40 IU/kg每周两次,出血≤1次者按1:1随机至每5天(45-60 IU/kg)或每7天(60 IU/kg)预防治疗26周。
  • 意向治疗人群共132例(预防治疗112例,按需治疗20例)。
  • 主要疗效终点为年化出血率(ABR)。

主要发现

  • 不符合随机化条件而继续每周两次治疗的患者(n=13)在剂量增加后中位ABR(四分位[Q1;Q3])从17.4(14.3;26.0)改善至4.1(2.0;10.6)。
  • 随机至每5天治疗的患者(n=43)中位ABR为1.9(0;4.2),与符合随机化条件但继续每周两次治疗的患者(n=11)相似。
  • 43例中32例(74%)继续每7天预防治疗至研究结束,其中位ABR为0.96(0.0;4.3)。
  • 702次出血中636次(90.6%)经≤2次输注得到控制。
  • 无患者产生因子VIII抑制物。

关键数值与推荐

  • 每5天预防治疗(45-60 IU/kg)中位ABR为1.9(0;4.2)。
  • 每7天预防治疗(60 IU/kg)中位ABR为0.96(0.0;4.3)。
  • 每周两次治疗不符合随机化条件者剂量增加后中位ABR从17.4(14.3;26.0)降至4.1(2.0;10.6)。

临床怎么用

  • BAY 94-9027可按每5天或每7天间隔用于重型A型血友病患者的预防治疗。
  • BAY 94-9027可用于出血治疗,多数出血经≤2次输注控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials Recombinant factor VIII BAY 94-9027 conjugates in a site-specific manner with polyethylene glycol. BAY 94-9027 was given to patients with severe hemophilia A as prophylaxis and to treat bleeds. BAY 94-9027 prevented bleeds at dose intervals up to every 7 days and effectively treated bleeds. BAY 94-9027 treatment was mainly well tolerated and no patient developed factor VIII inhibitors. Click to hear Dr Tiede's perspective on half-life extended factor VIII for the treatment of hemophilia A SUMMARY: Background BAY 94-9027 is a B-domain-deleted prolonged-half-life recombinant factor VIII (FVIII) that conjugates in a site-specific manner with polyethylene glycol. Objective Assess efficacy and safety of BAY 94-9027 for prophylaxis and treatment of bleeds in patients with severe hemophilia A. Patients/methods In this multinational, phase 2/3, partially randomized, open-label trial, men aged 12-65 years with FVIII < 1% and ≥ 150 exposure days to FVIII received BAY 94-9027 for 36 weeks on demand or prophylactically at intervals determined following a 10-week run-in period on 25 IU kg-1 body weight two times per week. Patients with > 1 bleed during the run-in subsequently received 30-40 IU kg-1 two times per week; patients with ≤ 1 bleed were eligible for randomization to every-5-days (45-60 IU kg-1 ) or every-7-days (60 IU kg-1 ) prophylaxis (1 : 1) for 26 additional weeks until randomization arms were filled. Patients who were eligible but not randomized continued twice-weekly prophylaxis. The primary efficacy outcome was annualized bleeding rate (ABR). Results The intent-to-treat population included 132 patients (prophylaxis, n = 112; on demand, n = 20). Median ABR (quartile [Q1; Q3]) for patients treated two times per week who were not eligible for randomization (n = 13) improved after dose increase (17.4 [14.3; 26.0] to 4.1 [2.0; 10.6]). Median ABR for patients randomized to every-5-days treatment (n = 43) was 1.9 (0; 4.2), similar to patients eligible for randomization but who continued treatment two times per week (n = 11). Median ABR for 32/43 patients (74%) who continued every-7-days prophylaxis until study end was 0.96 (0.0; 4.3). Six hundred and thirty-six of 702 bleeds (90.6%) were controlled with ≤ 2 infusions. No patient developed a FVIII inhibitor. Conclusions BAY 94-9027 prevented bleeding across three individually tailored dose regimens and was effective for treatment of bleeds.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Reding MT, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017. PMID: 27992112. doi:10.1111/jth.13597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。